Navigation Links
Fecal occult blood testing effective in colonoscopy screenings
Date:11/9/2011

Fecal immunochemical testing (FIT) is more effective in its health benefits at the same or lower costs compared to guaiac fecal occult blood testing (gFOBT) at all levels of colonoscopy capacity, according to a study published November 9 by the Journal of the National Cancer Institute.

In many countries, wait times for colonoscopy screenings can take up to 12 weeks. Screening with gFOBT has been proven to reduce mortality from colorectal cancer (CRC); however, the effectiveness of the screening depends partly on attendance at all screening rounds and on diagnostic yield (the proportion of individuals found with adenomas or CRC). FIT may increase attendance and diagnostic yield compared to gFOBT, and may cause fewer false positive tests. Because of these advantages, FIT is of increasing interest in the field.

To determine the benefits of FIT compared with gFOBT, Janneke A. Wilschut, MSc, of the department of public health at the University Medical Center in Rotterdam, the Netherlands, and colleagues used the MISCAN-Colon micro-simulation model, which simulates the relevant biographies of a large population from birth to death both without screening, as well as with changes that would occur in screening programs. The researchers estimated the number of colonoscopies, costs, and health effects of different screening strategies using both gFOBT and FIT, various age ranges and multiple surveillance strategies.

The model predicts that FIT is both cost-effective and clinically beneficial for detecting CRC. They found that for a screening scenario for people ages 45 to 80 years in which there is unlimited colonoscopy capacity, screening intensively with the lowest FIT cutoff level for referral to colonoscopy (50 ng hemoglobin per mL) provided optimal health benefits for cost. For a scenario with limited colonoscopy capacity, FIT with a higher cutoff level performed better than gFOBT and was more effective if the colonoscopy capacity was expanded.

The authors note certain limitations of the study: That they performed only one-way sensitivity analyses to evaluate the impact of other assumptions for some parameters and did not perform a probabilistic sensitivity analysis, stating that because of the large number of strategies needed to evaluate each draw a large computational effort would be required. Nevertheless, they conclude, "It should be noted that FOBT screening can become considerably more effective if colonoscopy capacity is expanded. Efforts should therefore be undertaken to achieve an increased colonoscopy capacity."

In an accompanying editorial, Russell Harris, M.D., MPH, of the Cecil G. Sheps Center for Health Services Research at the University of North Carolina at Chapel Hill and Linda S. Kinsinger, M.D., MPH, of the Department of Health Behavior and Health Education at the University of North Carolina School of Public Health, write that aggressive colonoscopy screening, termed "going the distance," in the United States has potential harms and costs that have not been fully explored. They discuss that the use of simulation models, such as the one described by Wilschut et al., could be useful to make real-world decisions about how intensive screening should be under different colonoscopy capacities by measuring clinical and cost effectiveness. However, such models do not incorporate the potential harms of aggressive screening programs, such as patient anxiety, the discomfort and inconvenience of the colonoscopy bowel preparation, sedation effects, loss of productivity at work and home, overdiagnosis, and the risk of complications from a biopsy and polypectomy, or take into account a situation in which resources are limited. Harris and Kinsinger suggest that outcomes tables are needed in addition to a simulation model to fully compare the benefits, harms, and costs of screening strategies. They suggest that such an analysis might reveal that a primary colonoscopy screening strategy ("going the distance"), as currently practiced in the US, provides less health value at higher cost than a strategy of restricting colonoscopic screening to smaller subgroups. In conclusion, "If not going the distance means fewer harms to patients, more participation by under-screened groups, fewer opportunity costs to the health-care system and lower overall cost for CRC screening, then less colonoscopy can mean more well-being for us all."


'/>"/>

Contact: Zack Rathner
Zachary.Rathner@oup.com
301-841-1286
Journal of the National Cancer Institute
Source:Eurekalert

Related medicine news :

1. Noninvasive fecal occult blood test effective screen for lower GI tract lesions
2. 1 in 6 Cellphones in Britain Contaminated With Fecal Matter
3. Fecal Transplants Show Promise for Gastrointestinal Ills
4. Inflammatory Bowel Ups Risk for Blood Clots
5. Bowel disease link to blood clots
6. Local Blood Supply Impacted by Wednesdays Severe Snow Storm
7. PERSONALABS Offers Discounted Healthy Heart Online Blood Tests in February
8. China Cord Blood Corporation Warrant Registration Statement Declared Effective by SEC
9. NIH grants to Childrens Hospital will advance novel stem cell treatments for blood disorders
10. Bilberry Seems to Act Against Blood Sugar
11. Johns Hopkins scientists develop personalized blood tests for cancer using whole genome sequencing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... 2016 , ... David J. Dykeman , Ginger Pigott , and ... speak at DeviceTalks West, Dec. 12, 2016, at the Fairmont Newport Beach in California. ... firm’s global Life Sciences & Medical Technology Group have been featured speakers at every ...
(Date:12/8/2016)... Tampa, Fla (PRWEB) , ... December 08, 2016 ... ... offering smarter modes of access for customers and employees that are both engaging ... ChangeGear 7 with Service Smart Technology, the software company revealed today its plans ...
(Date:12/8/2016)... ... 2016 , ... Catalent Pharma Solutions, the leading global provider ... products, today announced that it had joined the Pharmaceutical Supply Chain Initiative (PSCI). ... unite pharmaceutical and healthcare companies that share a vision of better, social, environmental ...
(Date:12/8/2016)... ... December 08, 2016 , ... STAT courier is pleased ... a convenient service for Texas, they are expanding their presence in Dallas. One of ... spree that will bring new jobs to the Dallas and Forth Worth market. STAT ...
(Date:12/8/2016)... ... December 08, 2016 , ... Today’s patients are encouraged to ... mind, SIGVARIS has created a new line of anti-embolism stockings to help prevent ... the benefits of graduated compression when transitioning from recovery to early rehabilitation. , ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... AMSTERDAM , December 8, 2016 Information ... TM metrics in Scopus , the world,s largest ... free access to comprehensive metrics for journals from over 5,000 publishers. ... publish, which journals to subscribe to and when to adjust a ... , , ...
(Date:12/8/2016)... 2016 According to the research report, ... is expected to be worth US$9.7 bn by the ... Between the forecast years of 2016 and 2024, the global ... The leading players operating in the global diabetes injection pens ... plc., Biocon Ltd., and Sanofi S.A. Transparency Market Research reports ...
(Date:12/8/2016)... 2016 According to a new market research report ... Therapeutic (Pain, Insulin)), End Use (Sports, Fitness, RPM), Type (Smart watch, Patch), ... global market, in terms of value, is projected to reach 12.14 Billion ... 18.0% during the forecast period. Continue Reading ... ...
Breaking Medicine Technology: